ygn2tvwb

Property	Value
?:abstract	BACKGROUND: Information regarding coronavirus disease 2019 (COVID-19) in haemodialysis (HD) patients is limited and early studies suggest a poor outcome. We aimed to identify clinical and biological markers associated with severe forms of COVID-19 in HD patients. METHODS: We conducted a prospective, observational and multicentric study. Sixty-two consecutive adult HD patients with confirmed COVID-19 from four dialysis facilities in Paris, France, from 19 March to 19 May 2020 were included. Blood tests were performed before diagnosis and at Days 7 and 14 after diagnosis. Severe forms of COVID-19 were defined as requiring oxygen therapy, admission in an intensive care unit or death. Cox regression models were used to compute adjusted hazard ratios (aHRs). Kaplan–Meier curves and log-rank tests were used for survival analysis. RESULTS: Twenty-eight patients (45%) displayed severe forms of COVID-19. Compared with non-severe forms, these patients had more fever (93% versus 56%, P < 0.01), cough (71% versus 38%, P = 0.02) and dyspnoea (43% versus 6%, P < 0.01) at diagnosis. At Day 7 post-diagnosis, neutrophil counts, neutrophil:lymphocyte (N:L) ratio, C-reactive protein, ferritin, fibrinogen and lactate dehydrogenase levels were significantly higher in severe COVID-19 patients. Multivariate analysis revealed an N:L ratio >3.7 was the major marker associated with severe forms, with an aHR of 4.28 (95% confidence interval 1.52–12.0; P = 0.006). After a median follow-up time of 48 days (range 27–61), six patients with severe forms died (10%). CONCLUSIONS: HD patients are at increased risk of severe forms of COVID-19. An elevated N:L ratio at Day 7 was highly associated with the severe forms. Assessing the N:L ratio could inform clinicians for early treatment decisions.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/ygn2tvwb_hasAnnotation_C0010200> <https://research.tib.eu/covid-19/entity/ygn2tvwb_hasAnnotation_C0013404> <https://research.tib.eu/covid-19/entity/ygn2tvwb_hasAnnotation_C0015967>
?:creator	<https://research.tib.eu/covid-19/entity/Mutinelli-Szymanski%2C_Prisca%3B_Hude%2C_Iulia%3B_Merle%2C_Emilie%3B_Lombardi%2C_Yannis%3B_Seris%2C_Pascal%3B_Abtahi%2C_Medhi%3B_Azeroual%2C_Latifa%3B_Bourgain%2C_Cecile%3B_Ensergueix%2C_Gael%3B_Katerinis%2C_Ioannis%3B_Kolko%2C_Anne%3B_Kolta%2C_Amir%3B_Maheas%2C_Catherine%3B_Mehrbanian%2C_Saeed%3B_Morel%2C_Pauline%3B_Ossman%2C_Rim%3B_de_Pr%C3%A9neuf%2C_H%C3%A9l%C3%A8ne%3B_Roux%2C_Arthur%3B_Saltiel%2C_Claudine%3B_Vend%C3%A9%2C_Florence%3B_Verhoeven%2C_Anne-Sophie%3B_Viron%2C_B%C3%A9atrice%3B_Laplanche%2C_Sophie%3B_Le_Monnier%2C_Alban%3B_Ridel%2C_Christophe%3B_Ure%C3%B1a-Torres%2C_Pablo%3B_Touzot%2C_Maxime>
?:doi	10.1093/ckj/sfaa194
?:doi	<https://research.tib.eu/covid-19/entity/10.1093/ckj/sfaa194>
?:journal	Clin_Kidney_J
?:license	cc-by-nc
?:pdf_json_files	document_parses/pdf_json/26b99195133dcaa5b80d4a34eda624753c255117.json
?:pmc_json_files	document_parses/pmc_json/PMC7717182.xml.json
?:pmcid	<https://research.tib.eu/covid-19/entity/PMC7717182>
?:pmid	<https://research.tib.eu/covid-19/entity/33558835.0>
?:pmid	33558835.0
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
?:sha_id	<https://research.tib.eu/covid-19/entity/26b99195133dcaa5b80d4a34eda624753c255117>
?:source	Medline; PMC
?:title	Neutrophil:lymphocyte ratio predicts short-term outcome of COVID-19 in haemodialysis patients
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-11-21

Property

Value

?:abstract

BACKGROUND: Information regarding coronavirus disease 2019 (COVID-19) in haemodialysis (HD) patients is limited and early studies suggest a poor outcome. We aimed to identify clinical and biological markers associated with severe forms of COVID-19 in HD patients. METHODS: We conducted a prospective, observational and multicentric study. Sixty-two consecutive adult HD patients with confirmed COVID-19 from four dialysis facilities in Paris, France, from 19 March to 19 May 2020 were included. Blood tests were performed before diagnosis and at Days 7 and 14 after diagnosis. Severe forms of COVID-19 were defined as requiring oxygen therapy, admission in an intensive care unit or death. Cox regression models were used to compute adjusted hazard ratios (aHRs). Kaplan–Meier curves and log-rank tests were used for survival analysis. RESULTS: Twenty-eight patients (45%) displayed severe forms of COVID-19. Compared with non-severe forms, these patients had more fever (93% versus 56%, P < 0.01), cough (71% versus 38%, P = 0.02) and dyspnoea (43% versus 6%, P < 0.01) at diagnosis. At Day 7 post-diagnosis, neutrophil counts, neutrophil:lymphocyte (N:L) ratio, C-reactive protein, ferritin, fibrinogen and lactate dehydrogenase levels were significantly higher in severe COVID-19 patients. Multivariate analysis revealed an N:L ratio >3.7 was the major marker associated with severe forms, with an aHR of 4.28 (95% confidence interval 1.52–12.0; P = 0.006). After a median follow-up time of 48 days (range 27–61), six patients with severe forms died (10%). CONCLUSIONS: HD patients are at increased risk of severe forms of COVID-19. An elevated N:L ratio at Day 7 was highly associated with the severe forms. Assessing the N:L ratio could inform clinicians for early treatment decisions.

is ?:annotates of